Biotechnology News and Research

RSS

Vitrolife second quarter sales increase 19% to SEK 88 million

Vitrolife: Second quarter in brief. Sales growth increased by 31 percent in local currency in the second quarter. Sales amounted to SEK 88 (73) million, corresponding to an increase by 19 percent in SEK.

14 Jul 2011

Accelrys releases Discovery Studio software for biotherapeutics research

Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced a new release of the Discovery Studio life sciences modeling and simulation software.

14 Jul 2011

Teva acquires Taiyo

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of effectively 100% of the outstanding shares of Taiyo Pharmaceutical Industry Co. Ltd. for $934 million in cash.

14 Jul 2011

Eisai's DACOGEN sNDA for acute myeloid leukemia accepted by FDA for review

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking approval of DACOGEN (decitabine) for injection in the treatment of acute myeloid leukemia.

14 Jul 2011

PharmAthene demonstrates 36 month stability of rPA anthrax vaccine program candidate

PharmAthene, Inc. announced today that it has achieved an important program milestone in its recombinant protective antigen (rPA) anthrax vaccine program and demonstrated 36 month stability of its rPA drug product candidate previously produced at Avecia Biologics Laboratories in the United Kingdom. The stability data were prepared utilizing a variety of analytical methods and a well characterized mouse challenge potency assay.

14 Jul 2011

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).

14 Jul 2011

JSPH, Worldwide Clinical Trials partner to meet demands of healthcare reform

Worldwide Clinical Trials Inc., a leading, global provider of clinical research services, and Thomas Jefferson University's School of Population Health (JSPH), under the direction of David B. Nash, MD, MBA, today announced that they have entered into an alliance to provide pharmaceutical and biotechnology clients with a broad range of outcomes research services including comparative effectiveness, burden of illness, and quality of life studies.

13 Jul 2011

Article describes predictors of post-TBI psychiatric disorders

A history of psychiatric illness such as depression or anxiety before a traumatic brain injury (TBI), together with other risk factors, are strongly predictive of post-TBI psychiatric disorders, according to an article published in Journal of Neurotrauma, a peer-reviewed journal published by Mary Ann Liebert, Inc.

13 Jul 2011

Sequana Medical's ALFApump System for liver cirrhosis receives CE Mark approval

Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump System.

13 Jul 2011

New Center for Nano Science and Technology: Italy

With a staff of 53 researchers of various nationalities, in a building of around 1,000 square metres, the Center for Nano Science and Technology is focused on technological innovation starting with basic research. In particular, the specific fields of application are photovoltaic conversion, biomimetic systems and plastic electronics.

12 Jul 2011

Affymetrix commences shipment of gene profiling reagents

Affymetrix, Inc. today began shipping its FDA-cleared Gene Profiling Reagents. Affymetrix also announced the availability of the new Gene Profiling Array cGMP U133 P2, a version of the widely cited Human Genome U133 Plus 2.0 Array, as another component to its GeneChip Instrument System, which is used by Affymetrix partners for assay development.

12 Jul 2011

Two studies on childhood leukemia

A difficult-to-treat form of childhood leukemia relies on changes in the structure of DNA - so-called epigenetic changes - to wreak genomic havoc within white blood cells, according to one of two studies conducted by a research team at Children's Hospital Boston and Dana-Farber Cancer Institute.

12 Jul 2011

genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents

genOway and bluebird bio report today genOway acquisition of an exclusive worldwide license for the RMCE technology (developed at the Massachusetts Institute of Technology) in the field of genetically modified rodents.

12 Jul 2011

Enrollment complete in Advaxis ADXS-HPV Phase II CIN study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed enrollment of the first 40 subject cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

12 Jul 2011

Sinapis completes first clinical trial of lead drug for stroke and traumatic brain injury

Sinapis Pharma, Inc. is pleased to announce that it has completed its first clinical trial in the development of its lead drug for the treatment of stroke and traumatic brain injury.

11 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

Generex announces convertible preferred stock securities purchase agreement

Generex Biotechnology Corporation today announced that it entered into a securities purchase agreement with certain institutional investors on July 8, 2011.

11 Jul 2011

Ion Torrent ships three next-generation sequencers

Ion Torrent, a unit of Life Technologies Corporation, today announced that it is shipping its new 100 Mb Ion 316 chip, which has tenfold more throughput than the original Ion 314 chip, and that its 1 Gb Ion 318 chip will be available in the fourth quarter.

11 Jul 2011

Nevada District Court rules in favor of PDL over Genentech, Roche lawsuit

PDL BioPharma, Inc. (PDL) announced a favorable ruling today, specifically, that on July 7, 2011, the Second Judicial District Court of Nevada ruled in favor of PDL on two motions to dismiss filed by Genentech and F. Hoffmann LaRoche, Ltd. in PDL's lawsuit related to the 2003 settlement agreement with Genentech.

11 Jul 2011

Probiomed, Vanda enter license deal to commercialize Fanapt in Mexico

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Probiomed S.A. de C.V., a wholly owned pharmaceutical operating unit of Proquifin S.A. de C.V., for the commercialization of Fanapt in Mexico.

11 Jul 2011